Sachin Jain
Stock Analyst at Bank of America Securities
(2.93)
# 2,868
Out of 4,662 analysts
274
Total ratings
53.9%
Success rate
2.2%
Average return
Main Sectors:
Stocks Rated by Sachin Jain
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: AZN AstraZeneca PLC | Maintained: Buy | 16,500p | 12,050p | +36.93% | 85 | Aug 17, 2026 | |
| LON: 0QIU Novo Nordisk A/S | Maintained: Hold | kr 350.00 | kr 292.75 | +19.56% | 29 | Aug 6, 2026 | |
| EPA: SAN Sanofi | Maintained: Hold | €92.00 | €78.56 | +17.11% | 23 | Jul 30, 2026 | |
| LON: GSK GSK plc | Reiterated: Hold | 2,350p | 1,916p | +22.65% | 15 | Jul 28, 2026 | |
| NVS Novartis AG | Maintained: Buy | n/a | $160.31 | - | 4 | Jul 21, 2026 | |
| SWX: NOVN Novartis AG | Reiterated: Buy | CHF 140.00 | CHF 127.12 | +10.13% | 27 | Jul 21, 2026 | |
| ETR: BAYN Bayer Aktiengesellschaft | Maintained: Buy | €30.00 → €35.00 | €49.01 | -28.59% | 9 | Dec 2, 2025 | |
| LON: 0MGB Genmab A/S | Maintained: Buy | kr 1,950 → kr 2,250 | kr 2,152 | +4.55% | 23 | Nov 25, 2025 | |
| BME: GRF Grifols, S.A. | Maintained: Buy | €10.60 | €10.08 | +5.16% | 1 | Nov 25, 2025 | |
| GSK GSK plc | Reiterated: Sell | $48 → $23 | $52.88 | -56.50% | 4 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $141 → $58 | $46.48 | +24.95% | 37 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | CHF 275.00 → CHF 340.00 | CHF 367.40 | n/a | 6 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €110.00 → €205.00 | €138.35 | n/a | 3 | Jun 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $48 → $49 | $34.11 | n/a | 4 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $24 | $30.35 | n/a | 1 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $195 | $174.38 | n/a | 1 | Jan 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $60 | $28.24 | n/a | 1 | Nov 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $183.17 | n/a | 1 | May 2, 2016 |
AstraZeneca PLC
Aug 17, 2026
Maintained: Buy
Price Target: 16,500p
Current: 12,050p
Upside: +36.93%
Novo Nordisk A/S
Aug 6, 2026
Maintained: Hold
Price Target: kr 350.00
Current: kr 292.75
Upside: +19.56%
Sanofi
Jul 30, 2026
Maintained: Hold
Price Target: €92.00
Current: €78.56
Upside: +17.11%
GSK plc
Jul 28, 2026
Reiterated: Hold
Price Target: 2,350p
Current: 1,916p
Upside: +22.65%
Novartis AG
Jul 21, 2026
Maintained: Buy
Price Target: n/a
Current: $160.31
Upside: -
Novartis AG
Jul 21, 2026
Reiterated: Buy
Price Target: CHF 140.00
Current: CHF 127.12
Upside: +10.13%
Bayer Aktiengesellschaft
Dec 2, 2025
Maintained: Buy
Price Target: €30.00 → €35.00
Current: €49.01
Upside: -28.59%
Genmab A/S
Nov 25, 2025
Maintained: Buy
Price Target: kr 1,950 → kr 2,250
Current: kr 2,152
Upside: +4.55%
Grifols, S.A.
Nov 25, 2025
Maintained: Buy
Price Target: €10.60
Current: €10.08
Upside: +5.16%
GSK plc
Oct 29, 2025
Reiterated: Sell
Price Target: $48 → $23
Current: $52.88
Upside: -56.50%
Oct 9, 2025
Maintained: Hold
Price Target: $141 → $58
Current: $46.48
Upside: +24.95%
Sep 13, 2024
Upgraded: Buy
Price Target: CHF 275.00 → CHF 340.00
Current: CHF 367.40
Upside: n/a
Jun 12, 2023
Maintained: Buy
Price Target: €110.00 → €205.00
Current: €138.35
Upside: n/a
May 11, 2023
Reiterated: Buy
Price Target: $48 → $49
Current: $34.11
Upside: n/a
Feb 2, 2023
Maintained: Hold
Price Target: $24
Current: $30.35
Upside: n/a
Jan 17, 2023
Maintained: Hold
Price Target: $195
Current: $174.38
Upside: n/a
Nov 1, 2022
Maintained: Buy
Price Target: $60
Current: $28.24
Upside: n/a
May 2, 2016
Maintained: Buy
Price Target: n/a
Current: $183.17
Upside: n/a